Hologic Inc.
Hologic Reports Third Quarter 2024 Financial Results with EPS Beat
Summary
Hologic, Inc. announced its financial results for the third quarter ended June 29, 2024, reporting GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $1.06, both exceeding guidance and the prior year's results. The company's total revenue for the quarter was $1,011.4 million, showing a 2.7% increase year-over-year. Non-GAAP measures, excluding COVID-19 revenues, demonstrated organic growth of 5.8%. The press release also provided guidance for the fourth quarter and full-year fiscal 2024, indicating continued positive performance expectations.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement